9 completed. 9 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 9 |
| Phase 1 | 3 | Completed 3 |
Follow Cilengitide: new trials by email Literature Review of Cilengitide trials Research Report on Cilengitide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status Cilengitide (2-times weekly), cilengitide (5-times weekly), Temozolomide - Glioblastoma | Phase 2 | Completed | EMD Serono | 265 | 2009-03-01 | 2017-01-30 |
| Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC) Cilengitide, Cetuximab, Cisplatin - Carcinoma, Non-Small-Cell Lung | Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 232 | 2009-02-01 | 2017-01-13 |
| Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Cilengitide 2000 mg once weekly, Cilengitide 2000 mg twice weekly, Cetuximab - Squamous Cell Cancer | Phase 1 / Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 184 | 2008-10-01 | 2014-04-30 |
| Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy cilengitide, laboratory biomarker analysis, pharmacological study - Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma | Phase 2 | Completed | National Cancer Institute (NCI) | 30 | 2008-06-01 | 2018-08-01 |
| Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme cilengitide, temozolomide, radiation therapy - Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 112 | 2005-04-01 | 2016-02-25 |
| Cilengitide in Treating Patients With Metastatic Prostate Cancer cilengitide, laboratory biomarker analysis - Recurrent Prostate Cancer, Stage IV Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 106 | 2005-01-01 | 2013-02-28 |
| Cilengitide in Treating Patients With Prostate Cancer cilengitide - Recurrent Prostate Cancer, Stage I Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 16 | 2005-01-01 | 2016-04-28 |
| Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor) Cilengitide 500 mg, Cilengitide 2000 mg - Glioblastoma Multiforme | Phase 2 | Completed | EMD Serono | 81 | 2004-10-13 | 2019-04-16 |
| EMD 121974 in Treating Patients With Progressive or Recurrent Glioma cilengitide - Brain and Central Nervous System Tumors | Phase 1 / Phase 2 | Completed | New Approaches to Brain Tumor Therapy Consortium | 2000-09-01 | 2013-06-24 |
Glioblastoma (4) · Astrocytoma (2) · Brain Neoplasms (2) · Gliosarcoma (2) · Oligodendroglioma (2) · Prostatic Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Central Nervous System Neoplasms (1) · Metatropic dwarfism (1) · Neoplasm Metastasis (1) · Neoplasms, Squamous Cell (1) · Optic Nerve Glioma (1) · Recurrence (1)
National Cancer Institute (NCI) (4) · EMD Serono (2) · Merck KGaA, Darmstadt, Germany (2) · New Approaches to Brain Tumor Therapy Consortium (1)
United States (7) · Germany (3) · Belgium (2) · France (2) · Italy (2) · Poland (2) · Spain (2) · Austria (1) · Canada (1) · Czechia (1) · Hungary (1) · Ireland (1) · Switzerland (1)
Maha Hussain (2) · Andriy Markivskyy, MD (1) · Jan Vermorken, MD, PhD (1) · Louis B. Nabors, MD (1) · Louis B. Nabors, Prof. Dr. (1) · Louis Nabors, MD (1) · Tobey MacDonald (1)
PMID 17470857, PMID 18981465, PMID 21049281, PMID 22517399, PMID 24567516, PMID 25939894, PMID 36346112
2008 (1), N01CM62202 (1), N01CM62206 (1), U01CA062475 (1), U10CA098543 (1)